GET DAILY SIGNALSRapport Therapeutics (RAPP) Q3 Results Show Clinical Progress Despite Higher Loss
Key Takeaways
- Rapport Therapeutics reported a third-quarter 2026 net loss of $40.2 million, or $0.84 per share, beating the consensus estimate of roughly -$1.20 per share.
- The headline for investors was clinical, not financial: the Phase 2 trial of RAP-219 in acute bipolar mania met its primary endpoint, building on earlier proof-of-concept in focal onset seizures (FOS).
- Research and development (R&D) spending rose to $34.3 million, up from $22.3 million a year earlier, as the company advanced multiple late-stage programs.
- The company ended the quarter with $395.0 million in cash and short-term investments, and roughly $815.4 million as of November 3, 2026 after recent financings, extending its runway through the end of 2029.
Earnings Context and Why It Matters
Rapport Therapeutics is a clinical-stage biotechnology company focused on precision small-molecule medicines for neurological and psychiatric disorders. Because the company has no approved products, quarterly earnings are less about revenue and more about two things: cash burn and clinical progress. Its lead candidate, RAPP, has now demonstrated proof-of-concept in two indications — FOS and bipolar mania — placing the company at a pivotal inflection point as it advances into late-stage trials. Investors closely track R&D spending and the balance sheet to gauge whether the company can fund multiple Phase 3 studies without excessive dilution, making this quarter's combination of a narrower-than-expected loss and a successful capital raise especially significant. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Rapport reported a net loss of $40.2 million, or $0.84 per share, compared with a net loss of $26.9 million, or $0.71 per share, in the prior-year period. The per-share result came in well ahead of consensus, which had anticipated a loss of approximately $1.20 per share.
R&D expense rose to $34.3 million from $22.3 million a year earlier, driven primarily by clinical development of RAP-219, including the Phase 3 FOS program and the completion of the bipolar mania Phase 2 trial. Selling, general and administrative (SG&A) expenses increased to $9.8 million from $7.7 million, reflecting headcount growth. The company ended the quarter with $395.0 million in cash, cash equivalents, and short-term investments, and management reiterated a cash runway extending through the end of 2029.
Market Reaction and Investor Sentiment
The stock's near-term reaction has been shaped more by pipeline news and financing activity than by the headline loss. On October 20, 2026, Rapport announced positive Phase 2 topline results for RAP-219 in acute bipolar mania, a milestone that reshaped the investment narrative by establishing clinical proof-of-concept in a second large indication. That optimism was partially offset by late-October equity and convertible-note offerings that pressured the share price, followed by an at-the-market (ATM) sale in early November. The third-quarter report itself, released November 4, 2026, confirmed the narrower-than-expected loss and reinforced the extended cash runway, offering investors a measure of reassurance on both execution and funding.
Forward Outlook and Key Factors to Monitor
The next several quarters will be defined by data readouts and regulatory milestones rather than bottom-line performance. Initial data from the open-label long-term safety trial in patients from the Phase 2a FOS study is expected in the fourth quarter of 2026, offering an early read on durability and tolerability.
Beyond that, investors will watch for the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 to discuss RAP-219 in bipolar mania, with initiation of two pivotal Phase 3 trials expected in the second half of 2027. A Phase 3 trial in primary generalized tonic-clonic seizures (PGTCS) is expected to begin in the first half of 2027, alongside continued enrollment in the FOCUS 1 and FOCUS 2 Phase 3 trials in FOS.
Cash management remains a key variable. The October 2026 financings — including common stock, pre-funded warrants, and $172.5 million of 2.25% convertible senior notes due 2032 — added roughly $410.7 million in net proceeds and extended the runway through 2029. Investors should monitor spending trajectories, trial timelines, and any additional dilution as the company scales its late-stage portfolio. From what I see, this extended runway gives the team room to execute without immediate pressure.
AI Tools in My Research Workflow
In my day-to-day analysis of clinical-stage names like RAPP, I frequently rely on Tickeron’s AI Screener to quickly surface comparable biotech names and assess technical setups alongside fundamentals. The tool lets me apply filters for market cap, volatility, and recent performance so I can put individual stories into broader context without spending hours on manual screens. It has become a reliable part of my routine when evaluating whether a clinical catalyst is likely to stand out or get lost in sector noise.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RAPP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RAPP turned positive on October 19, 2026. Looking at past instances where RAPP's MACD turned positive, the stock continued to rise in 28 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RAPP's RSI Oscillator exited the oversold zone, 5 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 25 of 28 cases where RAPP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where RAPP advanced for three days, in 124 of 140 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RAPP as a result. In 36 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for RAPP entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.691) is normal, around the industry mean (2.788). P/E Ratio (-7.828) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. RAPP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology